{"name":"Amytrx Therapeutics, Inc.","slug":"amytrx-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWm04emFZVFdWTUZEMEVaYmlpRFo5N24yc0dKeURtOEwxYlpNZmV0OEEwYmtjamJYTzd3WlFpR2RMTHpTUUx0U1Q0VFhJZGw0RkZoaDlFNGxoTXFEZFZMcHpjQXJvUWJ1NmUzLWFBT2VhbWRmMWxqRy1NcW9pY2h1LVhGblB1MHg2RjJ4R1JTWEFleUk0NGdpUC1hSmk?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Hypercholesterolemia Clinical Trial Pipeline Shows Potential - openPR.com","headline":"Hypercholesterolemia Clinical Trial Pipeline Shows Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"prnewswire.com","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"prnewswire.com","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - prnewswire.com","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOdmVHcWtfQUVGV01tRG1TYXV5M0NsU0cyM0JxRXVld3pKd1Q4RDlfbG5qYTlSaHdLMTg5NE8yWW9PRGFHSndBYllwMGFEZUpNLWpLS0lqekxTQkNxNUlBZmNobV9WbjRHOFNNaElzSkJlaFlNQ0kzYjBXSThnT2tvUVl6NmFOeFU0X2R5aV9IVkFnR0hxQ3ctc1pxb3ZBSUk4SjVmTTBWTWwtaFhJZkFPWDdoOUFzMXBsaGVYMGlDcWxDaXJKUmFrcGVGSzNZTDFldWtuaEpR?oc=5","date":"2023-07-25","type":"trial","source":"BioSpace","summary":"Amytrx Therapeutics' AMTX-100 Phase 1 Clinical Trial Data Presented at Revolutionizing Atopic Dermatitis Conference - BioSpace","headline":"Amytrx Therapeutics' AMTX-100 Phase 1 Clinical Trial Data Presented at Revolutionizing Atopic Dermatitis Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPWGZGa3YwRy1rQWkxamRRNWc0QXVRTlluOG8yc1VnOGMyb2IzWTlmX3ctOTh5Y0Jmd2MwYlBsU2dDUTFDZUJLU1BKb2xYYlpyaHNXZ2dKdzZjSUpUZzlNZGZQMjhaME0zcldnM1dQZjNkQmp4OVY4Ui14OVJHTzJ4cWNLMDRGRkM5R3hRbHQyUGRVcWR2Y3BmSEQtbWNNYVdWdDRnRDBQQkh3OFFqN044VHJEWkVCcUEyR3A1NUVuU0pHT0NXWFFScVRsX0lqdmJMR1l1VUZ1Y2NrZGliNHB5aG9jRUwydXF1MlpWdGZXenRaanFRTzQ5cldxQ2pES2REWTZ1OHNXTEhiU0lEYXYyazFmNFZoM1lXclRsa3V3N1FLdmlmemdEanlqMzBnaFlqRk5zOHlkY1pILVFZV3c?oc=5","date":"2023-06-28","type":"trial","source":"prnewswire.com","summary":"Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis - prnewswire.com","headline":"Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOUllaNHdIMHAyb1Q1aklmWTE3ZlI1a0pBaXRaN2lOUnYySGJmTmNlMXRoSnlwcmQ2Q3hrSWJOM1ViYXlraDVkc3drdjZuVS0xeXZnQll0SHF1R016Qm9LLWVVOWVDZHF5M19lVUFjU3BjT2gzU3RfY3ZSVExoWUlCaUl4VUxSX3JzVUdHY041YklsMUNFcmp1clZnbEVyYi1zNGtDc1E0X2Z4WmVjRzc3dzMzcjR3QkZsOVRBUVdkdW1OZTZmY2U1ekZjV3ltYml4YnRobVlUaFppTEtfbGsxT0ZpMzB0OE4xMVBQMkM0UEx0NXJtUE1MbUNfZmpSVFpFbmFQVkUxN0xaNHRGT25UWXJsUFIxSDRIMk5id185S1p2ZmhfczFxRkF4bE9ja1Y1RWNrbkcxRjIwLVdBVGl5cVo2TU5ET0Nqdk55QXJyY3lESlZyNzRv?oc=5","date":"2022-11-22","type":"earnings","source":"PR Newswire UK","summary":"With More than 150+ Molecules in Various Stages of Development, the Atopic Dermatitis Market to Witness Entry of New Drugs - Market Revenue to Cross USD 11 Billion by 2027 - Arizton - PR Newswire UK","headline":"With More than 150+ Molecules in Various Stages of Development, the Atopic Dermatitis Market to Witness Entry of New Dru","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPeXozS0tOVXp5WVVxRkF0XzVSbFBYWGVtenZpQ1NaU3lvMkFkZURYM1Q1OVkyYkw5U2o0RkFOd2NhaEpsV2xxVnBQNlVXbFpWNnoycEdYZWRWU1JTYklpYUZUUzR4X2NJTWY4LUl6NWFTRHB1VVZBVzdvMUFjVk9aMS1WOG1HM2gwTmZPYUZKdWcxcnJQZWk0QmFRT3A4NVZGdjRCZEo4MGRtZVBXVlBJdGpRbzF3T3R3dWJtZGU2TDJsZEZhYU9wLXgwLXNsZGlFNjE3VnUxZlZmN1U?oc=5","date":"2022-06-09","type":"trial","source":"prnewswire.com","summary":"Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis - prnewswire.com","headline":"Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOVmlDdTB0cndMZTlFQUtWUlh5VG5PeENPRkM1SGVjVUxDbnpBX3Z0VFlSTllKS2R6TEZ6LV92dmNmTnFhdWF4TF9zV0RqTlUyUTRlOFlaN1lUMHZrSWVldjFqRGpnTTJwZlBjRGRETkRHYjlOZjJmRXIxbkhMaDJxSUtSLUlsQk9Mb3JZaE9hbWJScF9rNUJQdUFqQmtJa0lNU2IxV0p4emNnRkVqZDRNbg?oc=5","date":"2020-09-18","type":"pipeline","source":"BioWorld News","summary":"Amytrx launches and puts its anti-inflammatory peptide into the clinic - BioWorld News","headline":"Amytrx launches and puts its anti-inflammatory peptide into the clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxNdVU2UGxOdmU0eHNrU1V3Y0JIeXhMNlYtSmFHa3J3X0R3SUxPQmRhZ1E2Z01zT19Ha2Z2MXlOTnlOU1VnbEd0djlKaTA4cHRmNTRuZjdfNlN0bFR1QWNsUVlDTWZ0dUxXc2w4bHMwb0ZaMGJweEFxQkk3YldUVUVkdUtPNkdxV2d0dWRKcmxObVQtdWo3bHB0cWxCTHFlQWFfVm1QQ0c5bm1wU3h0ZkJGT09vUHFELWVBOHhBZmIwZkZNTno5M0NKNHZ0SzU0eDZMSGtqaDNYOWo2LUFrUTdHSHVCMXlMMFNWWEM0aUM4Y25DTWVHOTFmUjZnaURUb2c4V1o2amt3ZTFHdmJyQTRJX0tMbzBQbUl4TDl6WFBhc19lUEdLUm1mY0daMU1LNkwwZmFnOGFaUjE1X3BjVUVvUElCeDZiRUJNOEpqb1JmU2ZXWU4zTFItMGpsRQ?oc=5","date":"2020-09-17","type":"pipeline","source":"prnewswire.com","summary":"Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100 Currently in Clinical Development for Dermatologic Indications - prnewswire.com","headline":"Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}